GH Research
Market cap $1.25B 68.7M shares (vendor count, Nov 18, 2026) × $18.27 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-15
Pipeline (4 active programs)
mebufotenin
GH002Capital (as filed)
- Cash
- $246M cash and cash equivalents · Dec 31, 2025 (20-F)
- Operating cash flow
- −$10.9M annual ÷ 4, year to Dec 31, 2025 (20-F)
- As stated in coverage
- $351M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-05-14 424B5 · At-the-market program up to $200M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-14 UPDATE: GH Research (GHRS) - Three Doses Become One, and 2026 Becomes 2027 🔒 Paid
- 2026-08-07 UPDATE: GH Research (GHRS) - The Factory Passed Inspection 🔒 Paid
- 2026-06-04 UPDATE: GH Research (GHRS) - The PPD Receipts Land (and They’re Loud) 🔒 Paid
- 2026-05-15 UPDATE: GH Research (GHRS) - The Bridging Gate Just Cleared (And a $200M ATM Joins the Party) 🔒 Paid
- 2026-04-29 UPDATE: GH Research (GHRS) - The Fortress Just Got Bigger (And They Used the Rip to Build It) 🔒 Paid
- 2026-04-27 UPDATE: GH Research (GHRS) - The White House Tailwind and a 54% Rip 🔒 Paid
- 2026-03-28 UPDATE: GH Research (GHRS) - Peer-Reviewed Receipts: GH001 Defies the STAR*D Paradigm 🔒 Paid
- 2026-03-07 UPDATE: GH Research (GHRS) - Q4/FY25 Update 🔒 Paid
- 2026-01-17 GH Research (GHRS): Scientific Deep Dive for GH001 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on GH Research, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-17 Buy speculative GH Research (GHRS): Scientific Deep Dive for GH001 Asymmetric risk/reward with massive cash protection, scalable 11-minute psychedelic treatment, and historic Phase 2b efficacy data following FDA hold lift.
- 2026-03-07 Hold UPDATE: GH Research (GHRS) - Q4/FY25 Update Core thesis intact with fortress balance sheet, but PK bridging study for new inhaler introduces execution risk and warrants a patient waiting game before Phase 3.
- 2026-03-28 Buy core UPDATE: GH Research (GHRS) - Peer-Reviewed Receipts: GH001 Defies the STAR*D Paradigm JAMA Psychiatry publication validates Phase 2b efficacy as scientific canon, and severity-independent remission rates upgrade scientific conviction to very high ahead of Phase 3.
- 2026-04-27 Hold UPDATE: GH Research (GHRS) - The White House Tailwind and a 54% Rip Thesis intact and strengthened by White House EO tailwind, but a 54% non-data rip elevates valuation risk and warrants trimming partial position while keeping core exposure.
- 2026-04-29 Hold UPDATE: GH Research (GHRS) - The Fortress Just Got Bigger (And They Used the Rip to Build It) Clean $117.5M raise led by Lynx1 at tight discount reinforces fortress balance sheet and fully funds Phase 3, with $18 as a credible re-engagement level for those who trimmed.
- 2026-05-15 Hold UPDATE: GH Research (GHRS) - The Bridging Gate Just Cleared (And a $200M ATM Joins the Party) Bridging study enrollment complete and Phase 3 doses selected removes the key execution gate, though new $200M ATM adds dilution overhang warranting patience around FDA Type B meeting.
- 2026-06-04 Buy core UPDATE: GH Research (GHRS) - The PPD Receipts Land (and They're Loud) JCP publication of PPD Phase 2a data with 100% remission and breastfeeding-compatible PK validates pipeline franchise narrative and strengthens M&A appeal alongside intact TRD thesis.
- 2026-08-07 Buy core UPDATE: GH Research (GHRS) - The Factory Passed Inspection FDA confirmed CMC and device plans appear Phase 3 ready, US patent granted to 2043, and European patent survived opposition, retiring the key execution and IP risks that kept conviction capped.
- 2026-11-14 Buy core UPDATE: GH Research (GHRS) - Three Doses Become One, and 2026 Becomes 2027 Phase 3 slips to post-Q1 2027 EoP2 meeting but device de-risked to single dose, trial design strengthened with blinded raters, Spravato veteran hired as CDO, and price reset near Lynx1's $18 entry.
- Long call · opened Jan 20, 2026 at $15.75 · +16.0% vs XBI +16.0% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (24)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 14, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 2026ReleaseGH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer Nov 13, 2026 Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs→ BD updateSummary on the 6-K
- Nov 13, 2026ReleaseGH Research Reports Third Quarter 2026 Financial Results and Provides Business Update Nov 13, 2026 Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support goi→ BD updateSummary on the 6-K
- Nov 13, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateGH Research's new ADS device just collapsed the pivotal-visit protocol from three doses to one — 88% peak experience rate in a single inhale — while the FDA signaled it likes the pivotal design and a former Spravato trial lead joins as CDO.
- Oct 9, 20266-KForeign issuer report
- Sep 11, 20266-KForeign issuer report
- Aug 6, 2026ReleaseGH Research Reports Second Quarter 2026 Financial Results and Provides Business Updatevia aggregatorBD extracted 1 program update from this document → GHRS pipeline
- Aug 6, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Jun 26, 20266-KForeign issuer report
- Jun 4, 2026ReleaseGH Research Announces Publication of Phase 2a Postpartum Depression Results Jun 04, 2026 DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of theBD extracted 1 program update from this document → GHRS pipeline
- Jun 4, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 21, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 14, 2026ReleaseGH Research Reports First Quarter 2026 Financial Results and Provides Business Update May 14, 2026 Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses s
- May 14, 2026F-3Shelf registration (foreign)
- May 14, 20266-KForeign issuer report
- May 14, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 14, 2026424B5Prospectus supplement (offering)
- May 13, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 13, 20266-KForeign issuer report
- Apr 30, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Apr 29, 2026424B5Prospectus supplement (offering)
- Mar 25, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 16, 20266-KForeign issuer report
- Mar 5, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 5, 202620-FAnnual report (foreign)
11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- May 19, 2026EFFECTRegistration effective
- May 18, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026UPLOADUPLOAD
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026CORRESPCORRESP
- Mar 5, 2026S-8Employee plan registration